Vertex Pharmaceuticals Incorporated
VRTX
$477.89
$3.620.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.69% | 4.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.69% | 3.77% | |||
| Cost of Revenue | 3.39% | 0.48% | |||
| Gross Profit | 3.94% | 6.66% | |||
| SG&A Expenses | 9.41% | 4.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.85% | 1.50% | |||
| Operating Income | 1.98% | 7.33% | |||
| Income Before Tax | 2.48% | 1.23% | |||
| Income Tax Expenses | -35.20% | -13.67% | |||
| Earnings from Continuing Operations | 9.99% | 4.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.99% | 4.84% | |||
| EBIT | 1.98% | 7.33% | |||
| EBITDA | -0.39% | 7.21% | |||
| EPS Basic | 10.73% | 5.29% | |||
| Normalized Basic EPS | 2.77% | 6.18% | |||
| EPS Diluted | 10.70% | 5.26% | |||
| Normalized Diluted EPS | 2.68% | 6.25% | |||
| Average Basic Shares Outstanding | -0.67% | -0.43% | |||
| Average Diluted Shares Outstanding | -0.58% | -0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||